// App-Quantinova.ai

POS-322 : Association of Changes in Modifiable Factors with Changes in KidneyIntelXTM Scores in the CANVAS Participants with Prevalent Diabetic Kidney Disease

Researchers

Presenter

  • G. Nadkarni

Principal Investigators

  • D. Takale

  • K. Chauhan

  • F. Fleming

  • H. Heerspink

  • S. Coca

Medical Centers

  • Persistent Systems, Biostatistics, Punai, India

  • Renalytix, Chief Technology Officer, New York, United States

  • Icahn School of Medicine at Mount Sinai, Internal Medicine, New York, United States

  • University of Groningen, Department of Clinical Pharmacy and Pharmacology, Groningen, Netherlands

Locations

  • India

  • United States

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Endocrine/metabolic Diseases (ME)

Disease

  • Diabetic nephropathy

  • Acute renal failure

Biomarkers

  • Hemoglobin A1c

  • Sex hormone binding globulin

Drug/Treatment

  • Canagliflozin

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved